関連レポート

モノクローナル抗体医薬品市場：2029年に至る製造法別、治療分野別予測

出版元：Transparency Market Research  出版元について

発行年：2023年12月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 211ページになります。

商品コード：TMR172

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

パーキンソン病治療薬の世界市場規模は2022年で51億ドル、2031年に92億ドル、市場の平均年成長率は7.0%で推移する見通しです。

当レポートでは、パーキンソン病治療薬の市場予測-2031年、各種セグメント別市場分析(薬剤クラス別、投与経路別、国地域別、等)、COVID-19の影響分析、市場シェア分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】
■パーキンソン病治療薬の世界市場予測2017-2031年
・市場規模(US$)

■薬剤クラス別、市場-2031年
レバドパ配合剤
ドパミン作動薬
MAO-B阻害薬
COMT阻害薬
その他
※(市場規模US$)

■投与経路別、市場-2031年
経口
経皮
皮下投与
腸管内注入
その他
※(市場規模US$)

■流通経路別、市場-2031年
病院薬局
小売薬局
オンライン薬局
※(市場規模US$)

■主要国地域別市場-2031年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
市場ダイナミクス（促進要因、障壁、機会）
COVID-19の影響
競合状況
市場シェア分析
SWOT分析

■パーキンソン病治療薬の主要企業プロフィール動向
AbbVie, Inc.
UCB Inc.
Merck & Co., Inc.
Valeant Pharmaceuticals International, Inc.
Novartis AG
Boehringer Ingelhelm GmbH
GlaxoSmithkline Plc
Teva Pharmaceutical Industries Ltd.
STADA Arzneimittel AG
（全211頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Parkinson’s Disease Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, 2017–2031

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Levodopa Combination
6.3.2. Dopamine Agonists
6.3.3. MAO-B Inhibitors
6.3.4. COMT Inhibitors
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class

7. Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Transdermal
7.3.3. Subcutaneous
7.3.4. Intestinal Infusion
7.3.5. Others
7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Parkinson’s Disease Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2017–2031
10.3.1. Levodopa Combination
10.3.2. Dopamine Agonists
10.3.3. MAO-B Inhibitors
10.3.4. COMT Inhibitors
10.3.5. Others
10.4. Market Value Forecast, by Route of Administration, 2017–2031
10.4.1. Oral
10.4.2. Transdermal
10.4.3. Subcutaneous
10.4.4. Intestinal Infusion
10.4.5. Others
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Hospital Pharmacy
10.5.2. Retail Pharmacy
10.5.3. Online Pharmacy
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Route of Administration
10.7.3. By Distribution Channel
10.7.4. By Country

11. Europe Parkinson’s Disease Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2017–2031
11.3.1. Levodopa Combination
11.3.2. Dopamine Agonists
11.3.3. MAO-B Inhibitors
11.3.4. COMT Inhibitors
11.3.5. Others
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Oral
11.4.2. Transdermal
11.4.3. Subcutaneous
11.4.4. Intestinal Infusion
11.4.5. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacy
11.5.2. Retail Pharmacy
11.5.3. Online Pharmacy
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Route of Administration
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region

12. Asia Pacific Parkinson’s Disease Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2017–2031
12.3.1. Levodopa Combination
12.3.2. Dopamine Agonists
12.3.3. MAO-B Inhibitors
12.3.4. COMT Inhibitors
12.3.5. Others
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Transdermal
12.4.3. Subcutaneous
12.4.4. Intestinal Infusion
12.4.5. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacy
12.5.2. Retail Pharmacy
12.5.3. Online Pharmacy
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Route of Administration
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region

13. Latin America Parkinson’s Disease Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2017–2031
13.3.1. Levodopa Combination
13.3.2. Dopamine Agonists
13.3.3. MAO-B Inhibitors
13.3.4. COMT Inhibitors
13.3.5. Others
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Transdermal
13.4.3. Subcutaneous
13.4.4. Intestinal Infusion
13.4.5. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacy
13.5.2. Retail Pharmacy
13.5.3. Online Pharmacy
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Route of Administration
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region

14. Middle East & Africa Parkinson’s Disease Therapeutics Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2017–2031
14.3.1. Levodopa Combination
14.3.2. Dopamine Agonists
14.3.3. MAO-B Inhibitors
14.3.4. COMT Inhibitors
14.3.5. Others
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Transdermal
14.4.3. Subcutaneous
14.4.4. Intestinal Infusion
14.4.5. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacy
14.5.2. Retail Pharmacy
14.5.3. Online Pharmacy
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Route of Administration
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region

15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. AbbVie, Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. UCB Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Merck & Co., Inc.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Valeant Pharmaceuticals International, Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Novartis AG
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Boehringer Ingelhelm GmbH
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. GlaxoSmithKline Plc
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Teva Pharmaceutical Industries Ltd.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. STADA Arzneimittel AG
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview

List of Tables

Table 01: Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 02: Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 03: Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 07: North America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 08: North America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 11: Europe Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 12: Europe Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 15: Asia Pacific Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 16: Asia Pacific Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 19: Latin America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 20: Latin America Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 23: Middle East & Africa Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 24: Middle East & Africa Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031

Figure 02: Global Parkinson’s Disease Therapeutics Market Revenue (US$ Mn), by Drug Class, 2022

Figure 03: Global Parkinson’s Disease Therapeutics Market Value Share, by Drug Class, 2022

Figure 04: Global Parkinson’s Disease Therapeutics Market Revenue (US$ Mn), by Route of Administration, 2022

Figure 05: Global Parkinson’s Disease Therapeutics Market Value Share, by Route of Administration, 2022

Figure 06: Global Parkinson’s Disease Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2022

Figure 07: Global Parkinson’s Disease Therapeutics Market Value Share, by Distribution Channel, 2022

Figure 08: Global Parkinson’s Disease Therapeutics Market Value Share, by Region, 2022

Figure 09: Global Parkinson’s Disease Therapeutics Market Value (US$ Mn) Forecast, 2023–2031

Figure 10: Global Parkinson’s Disease Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 11: Global Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031

Figure 12: Global Parkinson’s Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 13: Global Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031

Figure 14: Global Parkinson’s Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 15: Global Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031

Figure 16: Global Parkinson’s Disease Therapeutics Market Value Share Analysis, by Region, 2022 and 2031

Figure 17: Global Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Region, 2022-2031

Figure 18: North America Parkinson’s Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 19: North America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Country, 2023–2031

Figure 20: North America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Country, 2022 and 2031

Figure 21: North America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 22: North America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 23: North America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 24: North America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 25: North America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 26: North America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 27: Europe Parkinson’s Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 28: Europe Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 29: Europe Parkinson’s Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 30: Europe Parkinson’s Disease Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 31: Europe Parkinson’s Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 32: Europe Parkinson’s Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 33: Europe Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 34: Europe Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 35: Europe Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 36: Asia Pacific Parkinson’s Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 37: Asia Pacific Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 38: Asia Pacific Parkinson’s Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 39: Asia Pacific Parkinson’s Disease Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 40: Asia Pacific Parkinson’s Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 41: Asia Pacific Parkinson’s Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 42: Asia Pacific Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 43: Asia Pacific Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 44: Asia Pacific Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 45: Latin America Parkinson’s Disease Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 46: Latin America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 47: Latin America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 48: Latin America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 49: Latin America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 50: Latin America Parkinson’s Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 51: Latin America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 52: Latin America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 53: Latin America Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 54: Middle East & Africa Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 55: Middle East & Africa Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 56: Middle East & Africa Parkinson’s Disease Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 57: Middle East & Africa Parkinson’s Disease Therapeutics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 58: Middle East & Africa Parkinson’s Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 59: Middle East & Africa Parkinson’s Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 60: Middle East & Africa Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 61: Middle East & Africa Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 62: Middle East & Africa Parkinson’s Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

△ 一番上に戻る